ZIRGAN® (Zirgan®)

Archive
"Trade product
in Russia is not registered "
Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceGanciclovirGanciclovir
Similar drugsTo uncover
  • Ganciclovir
    lyophilizate d / infusion 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • ZIRGAN®
    gel d / eye 
    LABORATOUR TEA     France
  • Tzymoven
    lyophilizate in / in d / infusion 
    Hoffmann-La Roche Ltd.     Switzerland
    • Dosage form: & nbspeye gel
    Composition:

    1 g of eye gel contains:

    Active substance:

    Ganciclovir 1,5 mg

    Excipients:

    Benzalkonium chloride 75 μg, carbomer 4.83 mg, sorbitol 50 mg, sodium hydroxide sk. gt; to pH 7.4, water purified to 1 g.

    Description:Colorless gel.
    Pharmacotherapeutic group:Antiviral drugs
    ATX: & nbsp

    J.05.A.B.06   Ganciclovir

    S.01.A.D.09   Ganciclovir

    Pharmacodynamics:

    Ganciclovir is a nucleoside that inhibits the replication of human viruses Herpes Simplex first and second type.

    In infected cells ganciclovir is converted into the active form of ganciclovir - ganciclovirtriphosphate.

    Phosphorylation occurs predominantly in infected cells, and the concentration of ganciclovirtrisphosphate in uninfected cells is 10 times less.

    The antiviral activity of ganciclovirtriphosphate is to inhibit the synthesis of viral DNA using two mechanisms: competitive inhibition of viral DNA polymerase and direct incorporation into viral DNA in violation of chain termination and prevention of its replication.

    Pharmacokinetics:

    After instillation of the drug in the eye 5 times a day for 11-15 days in the treatment of superficial herpetic keratitis, the concentrations of ganciclovir in plasma were very low: an average of 0.013 μg / ml (0 = 0.037).

    Indications:

    Treatment of acute superficial keratitis caused by the herpes simplex virus.

    Contraindications:Hypersensitivity to ganciclovir, acyclovir or any of the components of the drug; pregnancy and lactation; children under 12 years.
    Dosing and Administration:

    Bury in the lower conjunctival sac of the affected eye 1 drop 5 times daily until complete corneal re-epithelialization, then 1 drop 3 times a day for 7 days.

    The duration of treatment should not exceed 21 days.

    Side effects:

    The most common side effects are blurred vision (60%), eye irritation (20%), spot keratitis (5%) and conjunctival hyperemia (5%).

    Overdose:

    There is no information about overdose.

    Interaction:Not found.
    Special instructions:
    This drug is not intended for the treatment of cytomegalovirus infection of the retina.

    The efficacy against keratoconjunctivitis caused by other types of virus was not established.

    No special studies have been conducted in patients with immunodeficiency. For women of childbearing age, contraception is necessary.

    Because of the genotoxicity found in animal experiments, it is recommended that men using ZIRGAN® use reliable contraceptive methods during treatment and within three months after its completion.

    Benzalkonium chloride can cause eye irritation and discoloration of soft contact lenses. Do not allow drug contact with soft contact lenses. Remove contact lenses before using the drug and reinstall them no earlier than 15 minutes after instillation.

    Effect on the ability to drive transp. cf. and fur:

    The patient should refrain from driving a car or working with complex equipment in case of any visual impairment during drug treatment.

    Form release / dosage:

    Eye gel 0.15%.

    Packaging:For 5 g of the drug in a tube with a tip and a screw cap.The tube, together with instructions for medical use and a removable stand, is placed in a cardboard box.
    Storage conditions:

    Store at a temperature not exceeding 25 ° C. In a place inaccessible to children.

    Shelf life:

    3 years. After opening the tube - 4 weeks.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-000988
    Date of registration:18.10.2011
    Expiration Date:18.10.2016
    Date of cancellation:2016-11-09
    The owner of the registration certificate: LABORATOUR TEA LABORATOUR TEA France
    Manufacturer: & nbsp
    Representation: & nbspSANTEN AS SANTEN AS Finland
    Information update date: & nbsp14.10.2017
    Illustrated instructions
      Instructions
      Up